Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results

International Journal of Surgery

Volumn 18, Issue , 2015, Pages 230-236

  Granata, V ^a   Fusco, R ^a   Piccirillo, M ^a   Palaia, R ^a   Petrillo, A ^a   Lastoria, S ^a   Izzo, F ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Electrochemotherapy; Pancreatic adenocarcinoma; Safety; Treatment assessment

Indexed keywords

AMYLASE; BLEOMYCIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CAMPTOTHECIN; DEOXYCYTIDINE; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AMYLASE BLOOD LEVEL; ARTICLE; ASCITES; BILIARY STENT; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; ELECTROCHEMOTHERAPY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEMODYNAMICS; HUMAN; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEEDLE ELECTRODE; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; SIDE EFFECT; SPLEEN INFARCTION; STOMACH FUNCTION DISORDER; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; ULTRASOUND; VENOUS STASIS; VERY ELDERLY; ADENOCARCINOMA; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; YOUNG ADULT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CAMPTOTHECIN; DEOXYCYTIDINE; ELECTROCHEMOTHERAPY; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ULTRASONOGRAPHY; YOUNG ADULT;

EID: 84930423290     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2015.04.055     Document Type: Article

References (41)

1. Cancer Research UK Pancreatic Cancer Statistics 2010, Available from: URL:. http://www.cancerresearchuk.org/cancerinfo/cancerstats/types/pancreas.
2. Cunningham D., Chau I., Stocken D.D., et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J.Clin. Oncol. 2009, 27:5513-5518.
3. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N.Engl. J. Med. 2011, 364:1817-1825.
4. VonHoff D.D., Ervin T.J., Arena F.P., et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J.Clin. Oncol. 2013, 30(Suppl.34). abstr LBA148.
5. Arcidiacono P.G., Carrara S., Reni M., et al. Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. Gastrointest. Endosc. 2012, 76:1142-1151.
6. Pai M., Yang J., Zhang X., et al. Endoscopic ultrasound guided radiofrequency ablation (EUSRFA) for pancreatic ductal adenocarcinoma. Gut 2013, 62(Suppl.1):A153.
7. Pai M., Senturk H., Lakhtakia S., et al. Endoscopic ultrasound guided radiofrequency ablation (EUS-RFA) for cystic neoplasms and neuroendocrine tumours of the pancreas. Gastrointest. Endosc. 2013, 77(5S). AB143-AB144.
8. Carrafiello G., Ierardi A.M., Fontana F., et al. Microwave ablation of pancreatic head cancer: safety and efficacy. J.Vasc. Interv. Radiol. 2013, 24:1513-1520.
9. Crowley J.M. Electrical breakdown of bimolecular lipid membranes as an electromechanical instability. Biophys. J. 1973, 13(7):711-724.
10. Neumann E., Rosenheck K. Permeability changes induced by electric impulses in vesicular membranes. J.Membr. Biol. 1972, 10(3):279-290.
11. Zimmermann U., Pilwat G., Riemann F. Dielectric breakdown of cell membranes. Biophys. J. 1974, 14(11):881-899.
12. Sugar I.P., Neumann E. Stochastic model for electric field-induced membrane pores electroporation. Biophys. Chem. 1984, 19(3):211-225.
13. Mir L.M., Orlowski S. Mechanisms of electrochemotherapy. Adv. Drug Deliv. Rev. 1999, 35(1):107-118.
14. Gehl J. Electroporation: theory and methods, prospectives for drug delivery, gene therapy and research. Acta Physiol. Scand. 2003, 177:437-447.
15. Jaroszeski M.J., Dang V., Pottinger C., et al. Toxicity of anticancer agents mediated by electroporation invitro. Anticancer Drugs 2000, 11:201-208.
16. Matthiessen L.W., Chalmers R.L., Sainsbury D.C.G., et al. Management of cutaneous metastases using electrochemotherapy. Acta Oncol. 2011, 50:621-629.
17. Matthiessen L.W., Johannesen H.H., Hendel H.W., et al. Electrochemotherapy for large cutaneous recurrence of breast cancer: a phase II clinical trial. Acta Oncol. Stockh. Swed. 2012, 51:713-772.
18. Allegretti J.P., Panje W.R. Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope 2001, 111(1):52-56.
19. Bloom D.C., Goldfarb P.M. The role of intratumour therapy with electroporation and bleomycin in the management of advanced squamous cell carcinoma of the head and neck. Eur. J. Surg. Oncol. 2005, 31(9):1029-1035.
20. Miklavčič D., Serša G., Brecelj E., et al. Electrochemotherapy: technological advancements for efficient electroporation-based treatment of internal tumors. Med. Biol. Eng. Comput. 2012, 50(12):1213-1225.
21. Edhemovic I., Brecelj E., Gasljevic G., et al. Intraoperative electrochemotherapy of colorectal liver metastases. J.Surg. Oncol. 2014, 10.1002/jso.23625.
22. Jaroszeski M.J., Illingworth P., Pottinger C., Hyacinthe M., Heller R. Electrically mediated drug delivery for treating subcutaneous and orthotopic pancreatic adenocarcinoma in a hamster model. Anticancer Res. 1999, 19(2A):989-994.
23. Marty M., Sersa G., Garbay J.R., et al. Electrochemotherapy - an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur. J. Cancer Suppl. 2006, 4:3-13.
24. Granata V., Fusco R., Piccirillo M., Palaia R., Lastoria S., Petrillo A., Izzo F. Feasibility and safety of intraoperative electrochemotherapy in locally advanced pancreatic tumor: a preliminary experience. Eur. J. Inflamm. 01/2014, 12(3):467-477.
25. He J., Page A.J., Weiss M., Wolfgang C.L., Herman J.M., Pawlik T.M. Management of borderline and locally advanced pancreatic cancer: where do we stand?. World J. Gastroenterol. 2014, 20(9):2255-2266.
26. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45(2):228-247.
27. Lavini C., de Jonge M.C., van de Sande M.G.H., Tak P., Nederveen J., Maas M. Pixel-by pixel analysis of DCE MRI curve patterns and an illustration of its application to the imaging of the musculoskeletal system. Mag. Reson. Imaging 2007, 25:604612.
28. Le Bihan D., Breton E., Lallemand D., Aubin M.L., Vignaud J., Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988, 168(2):497-505.
29. Fusco R., Petrillo A., Petrillo M., Sansone M. Use of tracer kinetic models for selection of semi-quantitative features for DCEMRI. Appl. Magn. Reson. 2013, 44(11):1311-1324.
30. Le Bihan D., Breton E., Lallemand D., Grenier P., Cabanis E., Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986, 161(2):401-407.
31. Deux A.J-F., Brugieres P., Rahmouni A. Liver cirrhosis: intravoxel incoherent motion MR imaging-pilot study. Radiology 2008, 249(3):891-899.
32. Girelli R., Frigerio I., Salvia R., Barbi E., Tinazzi Martini P., Bassi C. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br. J. Surg. 2010, 97:220-225.
33. Thomson K.R., Cheung W., Ellis S.J., et al. Investigation of the safety of irreversible electroporation in humans. J.Vasc. Interv. Radiol. 2011, 22:611-621.
34. Philips P., Hays D., Martin R.C. Irreversible electroporation ablation (IRE) of unresectable soft tissue tumors: learning curve evaluation in the first 150 patients treated. PLoS One 2013, 8:e76260.
35. Deodhar A., Dickfeld T., Single G.W., et al. Irreversible electroporation near the heart: ventricular arrhythmias can be prevented with ECG synchronization. AJR 2011, 196:W330-W335.
36. Appelbaum L., Ben-David E., Faroja M., et al. Irreversible electroporation ablation: creation of large-volume ablation zones in invivo porcine liver with four-electrode arrays. Radiology 2014, 270:416-424.
37. Bower M., Sherwood L., Li Y., Martin R. Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J.Surg. Oncol. 2011, 104:22-28.
38. Weiss M., Wolfgang C. Irreversible electroporation: a novel pancreatic cancer therapy. Curr. Probl. Cancer 2013, 37(5):261-265.
39. Månsson C., Nilsson A., Karlson B.M. Severe complications with irreversible electroporation of the pancreas in the presence of a metallic stent: a warning of a procedure that never should be performed. Acta Radiol. Short. Rep. 2014 Dec 3, 3(11).
40. Teissié J., Escoffrea J.M., Paganina A., Chabota S., Bellarda E., Wasungua L., Rolsa M.P., Golzioa M. Drug delivery by electropulsation: recent developments in oncology. Int. J. Pharm. 2012, 423:3-6.
41. Hjouj M., Last D., Guez D., Daniels D., Sharabi S., Lavee J., Rubinsky B., Mardor Y. MRI study on reversible and irreversible electroporation induced blood brain barrier disruption. PLoS One 2012, 7(8):e42817.